What is Genomind?
Genomind operates as a pharmacogenetic testing laboratory dedicated to personalized medicine within the psychiatric field. Composed of leading researchers and experts in psychiatry and neurology, the company focuses on uncovering the root causes of neuropsychiatric disorders. Genomind's commitment lies in developing personalized medicine approaches that tangibly enhance patients' lives. Founded by psychiatrist Ronald I. Dozoretz, MD, and neurologist Jay Lombard, DO, the organization is at the forefront of applying genetic science to mental health.
How much funding has Genomind raised?
Genomind has raised a total of $92.2M across 8 funding rounds:
Series A
$20.9M
Other Financing Round
$5M
Private Equity
$6M
Other Financing Round
$17.9M
Series B
$31.9M
Multiple Rounds
$10.4M
Series A (2014): $21M with participation from Claritas Capital
Other Financing Round (2014): $5M led by Claritas Capital
Private Equity (2015): $6M supported by Claritas Capital
Other Financing Round (2016): $18M featuring Claritas Capital
Series B (2017): $31.9M backed by Silicon Valley Bank
Debt (2020): $1M with participation from PPP
Series C (2020): $4.5M, investors not publicly disclosed
Series D (2020): $4.9M supported by Claritas Capital
Key Investors in Genomind
Claritas Capital
Claritas Capital is an alternative investments firm specializing in venture capital and real estate, with a focus on healthcare and technology sectors. They provide growth capital and strategic support to innovative companies.
Silicon Valley Bank
Silicon Valley Bank (SVB) is a financial institution offering a comprehensive suite of banking and financial services tailored to the technology and life sciences industries, including venture debt and commercial banking.
PPP
Public-Private Partnership
What's next for Genomind?
With substantial enterprise-level backing and a recent strategic investment, Genomind is poised for significant expansion. The company's trajectory suggests a focus on scaling its testing capabilities, broadening its research initiatives into complex neuropsychiatric conditions, and further integrating its genetic insights into clinical practice. This capital infusion will likely support enhanced data analytics, development of new diagnostic tools, and strategic partnerships aimed at making personalized psychiatric care more accessible and effective. The company's sustained access to capital indicates strong market confidence in its innovative approach to mental health.
See full Genomind company page
